Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RCT 2100

Next Previous
Drug Profile

RCT 2100

Alternative Names: Cystic fibrosis mRNA therapeutic - ReCode Therapeutics; RCT-2100

Latest Information Update: 03 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ReCode Therapeutics
  • Class Antifibrotics; RNA
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 29 Sep 2025 Phase-II clinical trials in Cystic fibrosis (Inhalation)
  • 28 Mar 2025 RCT 2100 receives Orphan Drug status for Cystic fibrosis in USA
  • 27 Sep 2024 Pharmacodynamics data from a preclinical trial in Cystic fibrosis released by ReCode Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top